Glioma biology is a major focus in tumour research, primarily due to the aggressiveness and high mortality rate of its most aggressive form, glioblastoma. Progress in understanding the molecular mechanisms behind poor prognosis of glioblastoma, regardless of treatment approaches, has changed the classification of brain tumours after nearly 100 years of relying on anatomopathological criteria. Expanding knowledge in genetic, epigenetic and translational medicine is also beginning to contribute to further elucidating molecular dysregulation in glioma. Long non-coding RNAs Gliomas are the most common type of brain malignancies and are accompanied by difficult diagnosis due to their high inter-and intratumoral heterogeneity. Glioblastoma multiforme (GBM) is the most heterogeneous and incurable glioma subtype. Recently, the WHO classification has been modified to include molecular criteria, such as IDH mutations for diffuse astrocytoma and GBM, or the epigenetic mark H3K27M mutation for diffuse midline glioma, to --
provide more precise diagnosis and treatment. 6 However, the quest for potential therapeutic targets remains unfulfilled; 7, 8 This review focuses on lncRNA-related mechanisms found to be activated in glioma molecular biology, some of which are significant to the developmental biology of the central nervous system, becoming aberrantly reactivated in adulthood. Several lncRNAs involved in embryogenesis that are found to be reactivated in brain tumour are discussed in the section dedicated to lncRNA functions in glioma biology. We will also review the two sides of lncRNA epigenetic regulation in glioma, as both targets and drivers. Finally, arguments in favour of using lncRNAs as diagnostic tools and therapeutic targets in glioma will be presented.
| BASIC CHARACTERISTICS AND FUNCTIONS OF LNCRNAS
Completion of human genome sequencing and de novo mammalian transcriptome characterization has revealed tens of thousands of lncRNA sequences emanating from uncharacterized genomic regions. 14, 15 LncRNA transcripts are lengthy (>200 nucleotides), often containing multiple functional domains capable of interacting with DNA, proteins or RNAs (mRNAs and microRNAs). The versatility of lncRNAs to fold into a variety of secondary and tertiary structures explains the diversity of their interacting partners and the complexity of their molecular functions.
Four types of molecular mechanism for lncRNAs have been distinguished, whereby lncRNAs act as signals, decoys, guides or scaffolds. 16, 17 Signal lncRNAs regulate transcriptional activity or signalling initiation. Decoy lncRNAs bind and titrate away gene regulatory elements (proteins, mRNAs, microRNAs). In the nucleus, lncRNAs can bind transcription factors (TFs) or chromatin modifiers, whereas in the cytoplasm, they function as a sponge to attract proteins and miRNA/RISC complexes away from their targets. In Table 1 , we summarized some of significant lncRNA-miRNA interactions with impact on glioma biology and pathology, where lncRNA is acting as competing endogenous to sponge miRNAs. Their interactions are discussed in detail in the next sections. Guide lncRNAs direct their molecular target (proteins) either in cis on neighbouring genes or in trans to distantly located genes. Scaffold lncRNAs bind and assemble multiple effector partners (proteins, RNAs) into complexes, controlling their formation and localization. 18, 19 Based on these characterized mechanisms, lncRNAs can initiate regulatory networks with high complexity at epigenetic, transcriptional and posttranscriptional levels required for cellular functions.
Though lncRNAs exhibit poor sequence conservation and are less expressed than are PCGs, they present the highest specificity with respect to cell type, subcellular compartment, developmental stage and in response to environmental stimuli. 11, 20, 21 LncRNAs play regulatory and structural roles in diverse cellular processes, including embryogenesis, stem cell pluripotency, differentiation and senescence. Interestingly, compared to that in other organs, the highest number of expressed lncRNAs has been found in the brain, and their number surpasses that of the brain PCG transcripts. 22 ,23 The brain's lncRNAs have the highest tissue specificity and are the most evolutionarily conserved, with similar spatiotemporal expression patterns across multiple species. [23] [24] [25] In neural development, lncRNAs have important roles in regulating stem cell maintenance and differentiation programmes, including cell fate specification 26 and neural lineage commitment. 27, 28 Under a complex programme of differentiation, partially controlled by lncRNAs, diverse types of neuroprogenitors develop into different neuronal and glial cell subtypes. 29 Moreover, differentially expressed lncRNAs across various stages of differentiation indicate that they can amplify and consolidate the molecular differences between cell types that are required to control cell identity and lineage commitment. 30 Some of these embryonically active programmes are reactivated during adulthood, primarily during oncogenic transformation, which will be discussed in this review. 32 For GBM, six lncRNAs were found to be significantly associated with patient prognosis but were independent of patient age or MGMT promoter methylation status. 38 One transcript, KIAA0495, was abundantly expressed in GBM tissues and associated with reduced survival. Myocardial infarction-associated transcript (MIAT/Gomafu), a neuron-specific component of the nuclear matrix 39 involved in neurogenesis and neural stem cells differentiation, 40 was identified as a significantly down-regulated lncRNA in glioma.
| DYSREGULATE D LN CRNA EXPRESSION IN GLIOMA PATHOL OGY
Gliomas can be classified into three different groups based on their dysregulated pattern of lncRNA expression and may be further associated with mutational status, molecular subtypes and clinical outcome. 41 In addition, an individual lncRNA can indicate stages in tumour progression and might be useful as an independent biomarker for diagnosis and prognosis. For example, the HOX transcript antisense RNA (HOTAIR) exhibits reduced expression in low-grade gliomas (LGG) compared with that in GBM. Furthermore, differentiated levels of expression between GBM subtypes were revealed, with higher levels of HOTAIR in classical and mesenchymal subtypes than those in proneural, a neural subtype. 37 Recently, hundreds of lncRNAs differentially expressed between glioma samples (grades I-IV) and normal brain tissues were identified and were subsequently associated with glioma pathology. 42 | 4599 in response to cell cycle, p53 and STAT3 pathway activation. 44 A novel four-lncRNA signature that accurately predicts survival in GBM patients was recently reported, and results of a functional analysis suggest that co-expressed genes tend to cluster within nine immunerelated processes and four biological pathways. 45 While dysregulation of lncRNAs has been correlated with glioma pathology and alteration of diverse signalling pathways, their functional significance in cancer is only beginning to be explored. Importantly, identification of key lncRNAs involved in neurogenesis and normal brain development (e.g CRNDE, HORAIRM1 and TUNA) as the most dysregulated lncRNAs in glioma suggests aberrant reactivation as a mechanism that promotes oncogenesis ( Figure 1 ).
| FUNCTIONS OF LNCRNAS IN GLIOMA BIOLOGY
The hallmark of brain tumours includes rapid cell proliferation, resistance to apoptosis, invasion of surrounding brain tissue, elevated levels of angiogenesis and the existence of therapy-resistant GSCs.
The functional role of lncRNAs is beginning to be validated by systematic experimental analysis of lncRNA activity and effects in normal and transformed cells, including both in vitro and in vivo models. 
| ONCOGENIC LNCRNAS
CRNDE, one of the most highly expressed lncRNAs during neuronal differentiation, in induced pluripotent stem cells (iPSCs) and within gliomas 32, 35, 50 exerts its oncogenic function by promoting glioma cell growth, invasion and migration through different signalling pathways. 51 Acting as a decoy, lncRNAs support glioma progression by reducing miR-136-5p expression, directly impacting PI3K/AKT/mTOR signalling pathways. 52 Knockdown of CRNDE combined with overexpression of miR-384 restrained glioma tumour growth and increased survival in a nude mouse model. CRNDE promotes GSC malignancy by negatively regulating miR-186. 31 Interestingly, the expression of CRNDE in stem cells is regulated by c-Myc, a multipotent TF that stimulates gene amplification and is overexpressed in many cancers, including glioma.
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SOX2OT is involved in neurogenesis and glioma development. 
55
NEAT1 is essential for nuclear paraspeckle formation and is overexpressed in most solid tumours. 56 The expression of NEAT1 is closely correlated with higher WHO grade and recurrence in gliomas. 31 Oncogenic NEAT1 depletion through the dual-CRISPR/Cas9 system inhibited GBM cell growth and invasion both in vitro and in vivo.
NEAT1 expression is regulated by EGFR pathway activity. Additionally, NEAT1 silencing in GBM cells affects the Wnt/β-catenin pathway, which is associated with early embryonic patterning and Nuclear MALAT1/NEAT2 is one of the most highly conserved lncRNAs among mammals and is significantly up-regulated in primary tissues and serum samples from GBM patients who exhibit resistance to TMZ-based treatment. 45 Furthermore, MALAT1 is more Linc CRNDE, colorectal neoplasia differentially expressed; Linc MIAT (Gomafu), myocardial infarction-associated transcript; HOTAIRM1, HOX antisense intergenic RNA myeloid 1; HOTAIR, HOX antisense intergenic RNA; Linc NEAT1, nuclear paraspeckle assembly transcript 1; Linc MALAT1/NEAT2, metastasis-associated lung adenocarcinoma transcript 1/nuclear paraspeckle assembly transcript 2; SOX2OT, SOX2 overlapping transcript; TUG1, taurine up-regulated 1; Linc XIST, X-specific inactive transcript; Linc-POU3F3, POU Class 3 homeobox 3 intergenic RNA; Linc TUNA, Tcl1 upstream neuronassociated/MEGAMIND; Linc-ROR, regulator of reprogramming; Linc MEG3, maternally expressed 3 long intergenic RNA; ADAMTS9-AS2, ADAMTS9 antisense RNA 2.
highly expressed in GSCs than it is in glioma tissues in general.
Oncogenic MALAT1 exerts a strong positive effect on GSC invasion, and its expression is regulated by WIF1 expression via the WNT5A/ p38-MAPK/Ca2 + -non-canonical WNT signalling axis 59 ( Figure 2 ). during hypoxia. 62, 63 TUG1 is expressed during retinal development and has numerous biological functions in cancer, acting primarily as an oncogene.
Overexpression of TUG1 in glioma cells leads to the alteration of apoptosis-related mediator proteins. 46 In addition, TUG1 is a downstream effector of the p53-regulatory network, promoting prolifera- probably by direct interaction. 71 Linc-POU3F3 is one of the few lncRNAs with evolutionarily conserved sequence and genomic location, and its expression is negatively correlated with its neighbouring gene, POU3F3. 72 As a TF, POU3F3 is involved in the regulation of key genes in the neurogenic differentiation of stem cells (DELTA1 and SOX2) and is required for maintaining the undifferentiated phenotype of neural precursors. 73 
F I G U R E 2 Mechanism of lncRNAs Involvement in Signalling Pathways
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| TUMOUR-SUPPRESSOR LNCRNAS
The cellular mechanism of tumour-suppressor lncRNAs consists of inhibiting uncontrolled cellular growth, migration and invasion or inducing apoptosis. MEG3 is highly expressed in normal brain tissue and is down-regulated in gliomas, inhibiting cell proliferation/ DNA synthesis by stimulating expression of p53 protein and modulating its binding to target gene promoters. 32, 47 Functional studies revealed that restored expression of MEG3 inhibited GBM cell proliferation and induced apoptosis as well as autophagy. 61 In MEG3 knockout mice, expression of genes involved in the VEGF angiogenic pathway and vascularization in the brain is affected. LincRNA-p21 is a p53-dependent transcriptional target gene involved in normal cellular proliferation, cell cycle and stem cell reprogramming. 30 In iPSC, lincRNA-p21 prevented reprogramming by activating epigenetic markers to induce heterochromatin at pluripotency gene promoters. 80 Moreover, lincRNA-p21 is down-regulated in many types of cancer, including gliomas and GSCs, behaving as a tumour suppressor. Functional studies revealed that lincRNA-p21 displays anti-EMT activity and suppresses Wnt/β-catenin signalling, leading to decreased cell viability, self-renewal and glycolysis in
GSCs. The overexpression of lincRNA-p21 dramatically decreased self-renewal capacity and tumorigenicity of GSCs in xenograft mice, and its silencing induced β-catenin overexpression, leading to increased stemness and radioresistance of GSCs. 81 To date, sufficient evidence has been gathered and tested regarding lncRNA involvement in glioma development. With special attention to particular areas of glioma biology, such as cancer stem cells, lncRNAs are bound to become active players in patient care, such as for prognostic and/or preventative purposes, or even for targeted treatment. Discussion will focus on epigenetic mechanisms influencing lncRNA dysregulation, as well as lncRNA-driven epigenetic changes in glioma.
| LNCRNA EPIGENE TICS IN GLIOMA
Epigenetics refers to the heritable and reversible modifications that affect gene expression and genomic stability without altering the DNA sequence. 82 The main epigenetic mechanisms comprise chemical modifications of DNA and histones (cytosine methylation, histone posttranslational modifications), chromatin remodelling and nucleosome positioning. These changes are reversible and controlled by enzyme complexes directly connected to metabolic and signalling pathways as well as sensors of extra-and intracellular microenvironments. 82 Ongoing research continues to uncover novel epigenetic pathways, including the important roles of non-protein-coding RNA transcripts (microRNAs and lncRNAs) in gene regulation as part of a larger epigenetic network. 83 Tumorigenesis results from a complex interplay of both genetic alterations and epigenetic changes affecting various cellular processes. In primary GBM, 80% of studied cases exhibit severe global hypomethylation of DNA. 6 The CpG island methylator phenotype is frequently found in secondary and recurrent GBM tumours and was correlated with high rates of IDH1 and TP53 mutations, early age of diagnosis and better prognosis. 4, 6 In GBM, genome-wide sequencing has identified an enormous number of mutations in epigenetic regulatory genes, including histone deacetylase (HDAC) 2 and 9, histone demethylases and methyltransferases. 84 Furthermore, globally altered expression levels of was inversely correlated with MEG3 transcript, supporting DNMT1's involvement in MEG3 dysregulation in glioma. 61 Importantly, the same association of MEG3 expression with promoter methylation status has been observed in hepatocellular cancer, and direct involvement of miR-29a, a DNMT1 and DNMT3B epigenetic modulator, was also demonstrated. 90 The activity of tumour suppressor ADAMTS9-AS2 is also controlled by DNA methylation in glioma.
Additionally, the expression of its transcript was positively correlated with ADAMTS9 and DNMT3A expressions. 76 A recent study showed that the lncRNA LOC285758 expression is regulated by DNA methylation and differs within glioma subtypes, with overexpression and higher promoter hypomethylation in GBM. 91 Histone modifications play an essential role in the regulation of lncRNA expression. LncRNA promoters exhibit specific histone marks, including methylated H3K4, H3K27, H3K36, and acetylated H3K9 and H3K27, suggesting that they undergo epigenetic regulation similar to that of PCG. 21 Genome-wide analysis in different cell and tissue types has revealed that highly expressed lncRNAs were however, epigenetic pathways can be important therapeutic targets.
| CONCLUSION AND PERSPECTIVES
Until now, a major unsolved issue with epigenetic therapy for cancer was target specificity. Through their peculiar features, such as tissue and genomic location specificity, and their modular structure interacting with several proteins involved in epigenetic mechanisms, lncRNAs might yield novel approaches for specific epigenometargeted therapies for gliomas or novel biomarkers for diagnostic, prognostic and monitoring purposes. 
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